Label: TRIMETHOBENZAMIDE HYDROCHLORIDE- trimethobenzamide hydrochloride injection 

  • NDC Code(s): 42023-142-01, 42023-143-25
  • Packager: JHP Pharmaceuticals, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application Authorized Generic

Drug Label Information

Updated 04/13

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Injectable

    For Intramuscular use only.

    Not for use in pediatric patients.

    Close
  • DESCRIPTION

    Chemically, trimethobenzamide hydrochloride (HCl) is N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula:

    Chemical Structure

    Single Dose Vials:

    Each 2-mL single-dose vial contains 200 mg trimethobenzamide hydrochloride compounded with 1 mg sodium citrate and 0.4 mg citric acid as buffers and pH adjusted to approximately 5.0 with sodium hydroxide.

    Multi-Dose Vials:

    Each mL contains 100 mg trimethobenzamide hydrochloride compounded with 0.45% phenol as preservative, 0.5 mg sodium citrate and 0.2 mg citric acid as buffers and pH adjusted to approximately 5.0 with sodium hydroxide.

    Close
  • CLINICAL PHARMACOLOGY

    Mechanism of Action

    The mechanism of action of trimethobenzamide hydrochloride as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

    Pharmacokinetics

    The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) trimethobenzamide hydrochloride IM injection, the time to reach maximum plasma concentration (Tmax) was about half an hour, about 15 minutes longer for trimethobenzamide hydrochloride 300 mg oral capsule than an IM injection. A single dose of trimethobenzamide hydrochloride 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to trimethobenzamide hydrochloride 200 mg IM. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48 – 72 hours. The metabolic disposition of trimethobenzamide in humans is not known. Specifically, it is not known if active metabolites are generated in humans.

    Special Populations

    Age

    The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of renal impairment. (See PRECAUTIONS: General and DOSAGE AND ADMINISTRATION.)

    Gender

    Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).

    Race

    Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).

    Renal Impairment

    The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See PRECAUTIONS: General and DOSAGE AND ADMINISTRATION.)

    Close
  • INDICATIONS

    Trimethobenzamide hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

    Close
  • CONTRAINDICATIONS

    The injectable form of trimethobenzamide hydrochloride is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

    Close
  • WARNINGS

    Trimethobenzamide hydrochloride may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.

    Usage in Pregnancy:

    Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no teratogenicity was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.

    Usage with Alcohol:

    Concomitant use of alcohol with trimethobenzamide hydrochloride may result in an adverse drug interaction.

    Close
  • PRECAUTIONS

    During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially in children and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms have been reported with and without use of trimethobenzamide hydrochloride or other antiemetic agents. In such disorders caution should be exercised in administering trimethobenzamide hydrochloride, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may result in cerebral edema.

    The antiemetic effects of trimethobenzamide hydrochloride may render diagnosis more difficult in such conditions as appendicitis and obscure signs of toxicity due to overdosage of other drugs.

    General

    Adjustment of Dose in Renal Failure

    A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION.)

    Geriatric Use

    Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that include elderly patients >65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION.)

    Close
  • ADVERSE REACTIONS

    There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.

    For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.

    Close
  • DOSAGE AND ADMINISTRATION

    (See WARNINGS and PRECAUTIONS.)

    Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.

    Geriatric Patients

    Dose adjustments such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with renal impairment (creatinine clearance ≤ 70 mL/min/1.73m2). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See CLINICAL PHARMACOLOGY and PRECAUTIONS.)

    Patients with Renal Impairment

    In subjects with renal impairment (creatinine clearance ≤ 70 mL/min/1.73m2), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION.)

    INJECTABLE, 100 mg/mL (Not for use in pediatric patients)

     
    Usual Adult Dosage
    2 mL (200 mg) t.i.d. or q.i.d. intramuscularly.

    NOTE: The injectable form is intended for intramuscular administration only; it is not recommended for intravenous use.

    Intramuscular administration may cause pain, stinging, burning, redness and swelling at the site of injection. Such effects may be minimized by deep injection into the upper outer quadrant of the gluteal region, and by avoiding the escape of solution along the route.

    Close
  • STORAGE

    Store between 20° to 25°C (68° to 77°F).
    (See USP Controlled Room Temperature.)

    Close
  • HOW SUPPLIED

    Single Dose Vials, 2 mL, trays of 25
    NDC 42023-143-25 100 mg/mL in 2 mL Single Dose Vials
    Multi-Dose Vials, 20 mL
    NDC 42023-142-01 100 mg/mL in 20 mL Multi-Dose Vials

    Close
  • SPL UNCLASSIFIED SECTION

    Rx Only
    Prescribing Information as of February 2012.

    Manufactured and Distributed by:
    JHP Pharmaceuticals, LLC
    Rochester, MI 48307

    3003198

    Close
  • PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton

    NDC 42023-142-01

    Trimethobenzamide
    Hydrochloride

    Injection

    2,000 mg/20 mL
    (100 mg/mL)

    NOT FOR USE IN CHILDREN

    For Intramuscular (IM) Use Only
    (preferably by deep IM injection)

    20 mL x 1 Multiple Dose Vial

    PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton
    Close
  • PRINCIPAL DISPLAY PANEL - 2 mL Vial Label

    NDC 42023-143-25

    Trimethobenzamide
    Hydrochloride

    Injection

    200 mg/2 mL
    (100 mg/mL)

    For Intramuscular
    Use Only

    PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton
    Close
  • INGREDIENTS AND APPEARANCE
    TRIMETHOBENZAMIDE HYDROCHLORIDE 
    trimethobenzamide hydrochloride injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:42023-142
    Route of Administration INTRAMUSCULAR DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    trimethobenzamide hydrochloride (trimethobenzamide) trimethobenzamide hydrochloride 100 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    Phenol  
    Sodium Citrate  
    Citric Acid Monohydrate  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:42023-142-01 1 in 1 CARTON
    1 20 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA authorized generic NDA017530 06/01/2012
    TRIMETHOBENZAMIDE HYDROCHLORIDE 
    trimethobenzamide hydrochloride injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:42023-143
    Route of Administration INTRAMUSCULAR DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    trimethobenzamide hydrochloride (trimethobenzamide) trimethobenzamide hydrochloride 100 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    Sodium Citrate  
    Citric Acid Monohydrate  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:42023-143-25 25 in 1 TRAY
    1 2 mL in 1 VIAL, SINGLE-DOSE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA authorized generic NDA017530 06/01/2012
    Labeler - JHP Pharmaceuticals, LLC (804894611)
    Close